“This FDA clearance will enable HBI to provide image processing services for two key clinical issues, deciding whether to intervene to stabilize a total knee replacement due to implant fixation concerns and deciding whether sufficient spine instability is present to justify spine fusion surgery,” said Chad Munro, CEO of Halifax Biomedical.
Halifax Biomedical is an evidence-based orthopedic clinical measurements company headquartered in Nova Scotia, Canada, with a U.S. office located in Cambridge, Mass.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
